Development of Delivery Systems Enhances the Potency of Cell-Based HIV-1 Therapeutic Vaccine Candidates

Figure 4

Transfection rates of DCs (b) and MSCs (d) with pEGFP-Nef using both Lipofectamine and equiaxial cyclic methods. Untransfected DCs (a) and MSCs (c) were shown as a negative control.

(a)

(b)

(c)

(d)